SOSV

Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.

Moirai Biodesign develops RNA-based therapies and diagnostics for cancer. The company develops non-invasive tests for in-vitro and in-situ diagnosis of AML using the patients blood; in-vivo diagnosis systems for surgical assistance and patient monitoring; and therapeutical drugs for treating cancer. Its pipeline includes RNA biomarker discovery, plug and play bio device design, and platform delivery system. The company was founded in 2016 and is based in Ireland.

Midoconline is a telehealth company focused on enhancing wellness through improved access to medical care and preventative measures. It offers a platform that enables patients to connect with healthcare professionals via video consultations, facilitating remote medical advice for non-emergency issues. The mobile application serves as a convenient tool for users seeking medical consultations, thereby promoting better health management and accessibility to healthcare services.

Aksense is an innovative company focused on developing affordable and portable nucleic acid-based diagnostic panels for the rapid and accurate detection of pathogens. Its flagship product is the first portable rapid infection diagnostic biosensor designed to improve healthcare quality and safety. By facilitating early detection and treatment of infections, Aksense's technology aims to enhance antibiotic prescribing practices and reduce the spread of infections. This approach not only improves patient outcomes but also supports public health initiatives by allowing users to recover faster through cost-effective molecular testing solutions.

AnimalBiome focuses on improving the gut health of dogs and cats in the United States that suffer from chronic digestive disorders. The company offers microbiome-based supplements and non-invasive diagnostic tools designed to identify imbalances in the gut microbiome. Utilizing deoxyribonucleic acid sequencing, AnimalBiome's diagnostic services assess the balance of gut bacteria, allowing pet owners to gain insights into their pets' gut health. This information enables tailored supplementation aimed at restoring gut balance, ultimately promoting a healthier and happier life for pets.

In India, 1 in 4 people suffer from chronic ailments. Meanwhile, 80% of patients cannot comply to the treatment plan provided by the doctor leading to even more complications. This poses a huge burden on the healthcare system. Phable solves this by making care autonomous and predictive. Our AI-enabled health assistant significantly improves health outcomes by enabling disease-specific guidance and continuous monitoring. Phable is marching onward to impact a billion lives over the next 5 years.

Conan MedTech, founded in 2020 and based in Ithaca, New York, specializes in the development of rapid point-of-care diagnostic tests for concussions. The company's innovative system is designed to facilitate real-time concussion detection, enabling sports medicine doctors, athletic coaches, and trainers to make informed decisions during games. By providing advanced and efficient medical assistance, Conan MedTech aims to enhance the diagnosis of mild traumatic brain injuries, ultimately improving patient care and outcomes.

Conan MedTech, founded in 2020 and based in Ithaca, New York, specializes in the development of rapid point-of-care diagnostic tests for concussions. The company's innovative system is designed to facilitate real-time concussion detection, enabling sports medicine doctors, athletic coaches, and trainers to make informed decisions during games. By providing advanced and efficient medical assistance, Conan MedTech aims to enhance the diagnosis of mild traumatic brain injuries, ultimately improving patient care and outcomes.

Midoconline is a telehealth company focused on enhancing wellness through improved access to medical care and preventative measures. It offers a platform that enables patients to connect with healthcare professionals via video consultations, facilitating remote medical advice for non-emergency issues. The mobile application serves as a convenient tool for users seeking medical consultations, thereby promoting better health management and accessibility to healthcare services.

PluriCell wants to positively impact the lives of millions of patients suffering from chronic heart failure condition by injecting healthy bona fide lab-made human heart cells in their failing heart, improve its function and, ultimately, the clinical outcome of the patients. Our tech enables us not only tackle heart diseases, but potentially, many chronic disorders currenly untractable.

Chronus Health, Inc. is focused on developing a portable diagnostic platform that delivers rapid point-of-care lab results, specifically for complete blood count and comprehensive metabolic panel tests. Founded in 2017 and headquartered in California, the company utilizes advanced microfluidics and semiconductor technology, combined with data analytics, to provide real-time diagnoses within minutes. This handheld device significantly enhances the ability of healthcare providers to access actionable data on-site, thereby improving patient outcomes and reducing the time to care. Chronus Health aims to transform the diagnostic process by enabling immediate treatment decisions based on accurate lab results.

Cellens is a spinoff company from Tufts University focused on enhancing cancer screening through noninvasive methods. The company has developed a cell surface scanning platform aimed at assisting oncologists in the detection of bladder cancer. Utilizing atomic force microscopy imaging combined with machine learning, Cellens' technology analyzes physio-biomarkers on cell surfaces derived from urine samples. This innovative approach generates a diagnostics score for bladder cancer, enabling healthcare providers, including oncologists and urologists, to minimize the need for invasive and costly diagnostic procedures. By improving the accuracy of bladder cancer detection, Cellens aims to optimize the patient experience and increase survival rates.

Cellens is a spinoff company from Tufts University focused on enhancing cancer screening through noninvasive methods. The company has developed a cell surface scanning platform aimed at assisting oncologists in the detection of bladder cancer. Utilizing atomic force microscopy imaging combined with machine learning, Cellens' technology analyzes physio-biomarkers on cell surfaces derived from urine samples. This innovative approach generates a diagnostics score for bladder cancer, enabling healthcare providers, including oncologists and urologists, to minimize the need for invasive and costly diagnostic procedures. By improving the accuracy of bladder cancer detection, Cellens aims to optimize the patient experience and increase survival rates.

VemiCo is a biotechnology company focused on extending healthy living by addressing the aging process. It utilizes artificial intelligence and synthetic biology to identify and develop promising molecules derived from gut microbial DNA. This innovative approach allows medical professionals to leverage the benefits of microbiomes, promoting gut health and enhancing overall well-being.

XN Health is a medical device company founded in 2021 and based in Texas, USA. The company specializes in developing innovative healthcare devices aimed at improving the weaning process for mechanically ventilated patients. Its primary product utilizes phrenic nerve stimulation to induce diaphragm contractions, which helps mitigate diaphragm dysfunction often caused by prolonged mechanical ventilation. This technology enables patients to transition off ventilators more quickly and safely, addressing a critical challenge in critical care settings.

Criam is a biotechnology company based in Braga, Portugal, founded in 2015, that focuses on developing medical devices for blood type analysis and disease detection. The company's flagship product, also named Criam, enables rapid and affordable blood test analysis, allowing users to receive immediate information about their health. This medical device can detect various diseases, including HIV, Brucella, tick fever, syphilis, mononucleosis, and meningitis. By positioning itself in the Point-of-Care diagnostic segment, Criam aims to empower individuals with timely health information and contribute to the global monitoring and control of diseases.

BioSapien is a biotech startup that focuses on developing a 3D printed drug delivery platform to provide FDA approved drugs. The startup's device allows chemotherapy to be delivered intravenously through a controlled drug release and enables physicians to reduce harmful side-effects and dramatically reduce costs. BioSapien was established in 2018 and is based in New York.

Sequential Skin is a diagnostic platform company targeting skin longevity and aging. Our team specialises in genetics, epigenetics, and the skin microbiome.

Every day we flush precious information on our bodies down the toilet. Bisu helps people capture these data and lead healthier, happier lives. Our product is a home health lab that provides personalized advice to help you look, feel and perform at your best, through easy, accurate urine and saliva tests. We are graduates of HAX, the world's leading hardware accelerator, and have won numerous awards including Johnson & Johnson Innovation, MedTech Innovator, the Edison Awards, UK Tech Rocketship Awards and the British Business Awards. At CES 2020 we won the IHS Markit Innovation Award and were named by CNET as one of the top health-tracking devices.

Sequential Skin is a diagnostic platform company targeting skin longevity and aging. Our team specialises in genetics, epigenetics, and the skin microbiome.

Rizlab Health is a medical device startup founded in 2018 and based in East Princeton. The company specializes in providing practitioners and patients with rapid blood count readings, specifically focusing on white blood cell analysis. Rizlab Health's electronic cytometer and analyzer utilize a cartridge system to quantify key cellular components, such as neutrophils and lymphocytes. This technology enables hospitals and healthcare providers to quickly and affordably monitor patients' white blood counts, which is crucial for diagnosing conditions like sepsis and distinguishing between bacterial and viral infections. By offering a fast, portable, and cost-effective health monitoring solution, Rizlab Health aims to enhance patient care and streamline clinical decision-making processes.

Rizlab Health is a medical device startup founded in 2018 and based in East Princeton. The company specializes in providing practitioners and patients with rapid blood count readings, specifically focusing on white blood cell analysis. Rizlab Health's electronic cytometer and analyzer utilize a cartridge system to quantify key cellular components, such as neutrophils and lymphocytes. This technology enables hospitals and healthcare providers to quickly and affordably monitor patients' white blood counts, which is crucial for diagnosing conditions like sepsis and distinguishing between bacterial and viral infections. By offering a fast, portable, and cost-effective health monitoring solution, Rizlab Health aims to enhance patient care and streamline clinical decision-making processes.

Microgenesis SA is a biotechnology company focused on developing medical technologies and treatments for reproductive health. Established in 1992 and based in San José de la Rinconada, Spain, the company specializes in non-invasive tests that identify imbalances in vaginal and intestinal microbiota linked to infertility. Additionally, Microgenesis offers dual tests to assess microbiota imbalances related to endometrial immunological issues and provides tools and guidance for managing complex reproductive health cases. Their innovative fertility test and treatment aim to restore fertility potential, particularly for women who have previously experienced multiple IVF failures. Operating from a CLIA-certified lab in Oakland, Microgenesis emphasizes a drug-free, all-natural three-month treatment that addresses subclinical inflammation adversely affecting ovarian function and implantation.

Advanced Microbubbles Inc specializes in the development of microbubbles, which serve as ultrasound contrast agents for targeted drug delivery. Founded in 2020 and based in Newark, California, the company offers a range of products, including size-isolated microbubbles and biotin- or streptavidin-tagged variants. These microbubbles are designed for applications in ultrasound imaging, noninvasive cancer surgery, and enhancing drug delivery across challenging biological barriers, such as the blood-brain barrier. By focusing on precision drug and gene delivery, Advanced Microbubbles aims to improve treatment outcomes and reduce side effects for patients with neurological conditions and cancer.

EIO Diagnostics Inc. is a Canadian company that focuses on developing innovative solutions for dairy farmers, specifically targeting the early detection of mastitis infections in dairy animals. Founded in 2017 and headquartered in Duncan, Vancouver, the company has created the FirstLook Mastitis detection system, which employs a multispectral sensor to capture images of the udder as animals enter the milk parlor. This technology utilizes artificial intelligence and computer vision to identify early indicators of infection, enabling farmers to take preventive measures. By automating the mastitis detection process, EIO Diagnostics aims to enhance livestock health, improve milk quality, and reduce the labor and costs associated with managing udder infections.

Strados Labs, LLC is a medical technology company based in Philadelphia, Pennsylvania, that focuses on innovating respiratory health management through advanced biosensors and artificial intelligence. Founded in 2016, Strados Labs develops a wearable device that provides real-time insights into respiratory metrics such as breathing speed, sounds, and patterns. This device is equipped with a continuous breathing sensor that enables remote monitoring of patients with respiratory conditions like asthma and chronic obstructive pulmonary disease. By connecting the device to a mobile application, patients and healthcare providers can access critical respiratory data, facilitating informed decision-making and improved management of respiratory health.

Strados Labs, LLC is a medical technology company based in Philadelphia, Pennsylvania, that focuses on innovating respiratory health management through advanced biosensors and artificial intelligence. Founded in 2016, Strados Labs develops a wearable device that provides real-time insights into respiratory metrics such as breathing speed, sounds, and patterns. This device is equipped with a continuous breathing sensor that enables remote monitoring of patients with respiratory conditions like asthma and chronic obstructive pulmonary disease. By connecting the device to a mobile application, patients and healthcare providers can access critical respiratory data, facilitating informed decision-making and improved management of respiratory health.

Filtricine, Inc. is a clinical-stage biotechnology company based in Santa Clara, California, focused on developing therapeutic products for cancer treatment. Founded in 2017, the company specializes in a novel nutrient modulation platform that targets and depletes essential nutrients critical for cancer cell growth. By exploiting the metabolic vulnerabilities of cancer cells, Filtricine aims to halt the spread of cancer without relying on traditional drug substances. This approach allows healthcare professionals to utilize targeted nutrient deprivation therapy to address a broad spectrum of cancers effectively.

We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity Ranking, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access to precision oncology to improve patients' lives.

The CareVoice Limited is a Shanghai-based company that develops a mobile-based, data-driven software as a service (SaaS) solution aimed at enhancing the healthcare experience in China. Founded in 2013, the company provides a platform that features community-sourced ratings and recommendations for hospitals, doctors, and treatments. Patients can share their experiences through ratings and reviews based on their medical visits, fostering a collaborative environment for individuals undergoing similar treatments. The CareVoice aims to transform healthcare into a more consumer-centric experience, offering tools for insurers to create connected health ecosystems and improve patient engagement. The company also maintains an office in Hong Kong and has garnered support from prominent venture capital and healthcare investors.

Japet Medical Devices SAS, founded in 2016 and headquartered in Lille, France, focuses on the development of robotic medical devices aimed at enhancing health and quality of life. The company specializes in wearable robotic exoskeletons, notably the Atlas device, which is designed for individuals suffering from back pain. By integrating medical and robotic technologies, Japet's products aim to restore balance and facilitate free movement while providing pain relief through orthosis. The company's commitment to creating efficient and user-friendly solutions underscores its dedication to improving the lives of those affected by mobility challenges.

Sequential Skin is a diagnostic platform company targeting skin longevity and aging. Our team specialises in genetics, epigenetics, and the skin microbiome.

Diadem Biotherapeutics is a biotechnology company that focuses on creating bio-therapeutical materials produced using organic means. Diadem develops exosomes to treat chronic inflammatory and auto-immune conditions.

Criam is a biotechnology company based in Braga, Portugal, founded in 2015, that focuses on developing medical devices for blood type analysis and disease detection. The company's flagship product, also named Criam, enables rapid and affordable blood test analysis, allowing users to receive immediate information about their health. This medical device can detect various diseases, including HIV, Brucella, tick fever, syphilis, mononucleosis, and meningitis. By positioning itself in the Point-of-Care diagnostic segment, Criam aims to empower individuals with timely health information and contribute to the global monitoring and control of diseases.

AnimalBiome focuses on improving the gut health of dogs and cats in the United States that suffer from chronic digestive disorders. The company offers microbiome-based supplements and non-invasive diagnostic tools designed to identify imbalances in the gut microbiome. Utilizing deoxyribonucleic acid sequencing, AnimalBiome's diagnostic services assess the balance of gut bacteria, allowing pet owners to gain insights into their pets' gut health. This information enables tailored supplementation aimed at restoring gut balance, ultimately promoting a healthier and happier life for pets.

JointechLabs, Inc. is a company focused on enhancing access to cell-based therapies for healthcare providers and patients. Based in Mount Prospect, Illinois, the company has developed the Mini-Stem System, a closed disposable kit designed for the processing and extraction of stromal vascular cell fractions from human tissue. This innovative medical device allows for the efficient preparation of high-quality injectable fat grafts and fat-derived stem cells, facilitating on-site access to optimized adipose-derived stromal cells (ADSC). By streamlining the process of individualized cell and tissue-based therapies, JointechLabs aims to make these advanced treatments more accessible and cost-effective for use in hospitals, clinics, and local medical offices. Since its incorporation in 2012, the company has been dedicated to improving the efficacy and availability of cell therapies in clinical settings.

Mendel.ai develops artificial intelligence-based solutions aimed at enhancing clinical oncology research and improving patient care. Founded in 2005 and headquartered in San Jose, California, the company offers a range of software solutions that address various challenges in the clinical trial process. Its products include Read, which provides instant data abstraction; Retina, designed to minimize data loss during optical character recognition; Redact, which addresses privacy concerns in patient record sharing; Research, a clinical search engine; Recruit, facilitating patient prescreening and enrollment; and Enrich, which offers real-time access to real-world data from leading oncology clinics. By transforming unstructured electronic medical records and clinical literature into analytics-ready data, Mendel.ai aims to streamline global oncology research and automate clinical trials.

BiomeSense is revolutionizing human microbiome research by developing novel technologies to enable investigators to collect, store, and analyze the daily microbiome profiles of clinical trial participants in a low-cost, scalable way. By enabling daily profiling, the platform allows investigators the unprecedented ability to tie microbiome changes directly to clinical outcomes in real time, dramatically increasing the research discovery potential.

FluidAI Medical is focused on developing an innovative implantable biochip equipped with biosensors designed to detect post-operative complications, including internal bleeding, fluid leakage, and infections within the abdominal cavity. This advanced biosensor continuously collects data, identifying complications as they arise, and provides real-time notifications to both patients and healthcare providers. Specifically, the device aims to manage risks associated with surgeries by monitoring for anastomotic leakage, which involves gastrointestinal fluid leaking into the abdominal cavity. The biosensor is integrated into a catheter, where it resides within the abdominal cavity, while a monitoring unit remains external. When the biosensor detects changes indicative of a leak, it transmits alerts through the catheter to the external monitor. Data is continuously uploaded to the cloud for further analysis, ensuring timely alerts are sent to patients' smartphones, prompting them to seek medical attention, while offering detailed information to their doctors. Founded in 2014 and based in Kitchener, Canada, FluidAI Medical serves physicians, surgeons, hospitals, and patients with its groundbreaking technology.

DeepSpin GmbH, founded in 2019 and headquartered in Berlin, Germany, specializes in the development of an innovative artificial intelligence (AI)-based magnetic resonance imaging (MRI) system. This next-generation imaging machine is designed to be significantly smaller, lighter, and more affordable than conventional MRI systems. By utilizing generative topological design for its hardware and deep learning algorithms for image processing, DeepSpin aims to enhance the accessibility of medical imaging, making it available to patients worldwide. The company's technology seeks to modernize medical imaging, providing a standard of care that can reach previously underserved medical domains.

Medical Devices Corner specializes in providing commercial medical products.

Chronus Health, Inc. is focused on developing a portable diagnostic platform that delivers rapid point-of-care lab results, specifically for complete blood count and comprehensive metabolic panel tests. Founded in 2017 and headquartered in California, the company utilizes advanced microfluidics and semiconductor technology, combined with data analytics, to provide real-time diagnoses within minutes. This handheld device significantly enhances the ability of healthcare providers to access actionable data on-site, thereby improving patient outcomes and reducing the time to care. Chronus Health aims to transform the diagnostic process by enabling immediate treatment decisions based on accurate lab results.

We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity Ranking, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access to precision oncology to improve patients' lives.

We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity Ranking, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access to precision oncology to improve patients' lives.

We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity Ranking, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access to precision oncology to improve patients' lives.

Kite Medical Ltd. is a Galway, Ireland-based company that specializes in developing a non-invasive device for detecting kidney reflux in children with urinary tract infections. Founded in 2016, the company focuses on providing a diagnostic solution that eliminates the need for complicated procedures and hospital visits. Kidney reflux, the most common urological disorder in childhood, affects up to three percent of young children, particularly those aged six months to five years. If left undiagnosed and untreated, the condition can lead to serious complications, including permanent kidney damage and kidney failure. Kite Medical's innovative technology aims to enhance the patient experience and improve clinical outcomes by enabling early detection and monitoring of kidney reflux in a safe and efficient manner.

Sequential Skin is a diagnostic platform company targeting skin longevity and aging. Our team specialises in genetics, epigenetics, and the skin microbiome.

In India, 1 in 4 people suffer from chronic ailments. Meanwhile, 80% of patients cannot comply to the treatment plan provided by the doctor leading to even more complications. This poses a huge burden on the healthcare system. Phable solves this by making care autonomous and predictive. Our AI-enabled health assistant significantly improves health outcomes by enabling disease-specific guidance and continuous monitoring. Phable is marching onward to impact a billion lives over the next 5 years.

Microgenesis SA is a biotechnology company focused on developing medical technologies and treatments for reproductive health. Established in 1992 and based in San José de la Rinconada, Spain, the company specializes in non-invasive tests that identify imbalances in vaginal and intestinal microbiota linked to infertility. Additionally, Microgenesis offers dual tests to assess microbiota imbalances related to endometrial immunological issues and provides tools and guidance for managing complex reproductive health cases. Their innovative fertility test and treatment aim to restore fertility potential, particularly for women who have previously experienced multiple IVF failures. Operating from a CLIA-certified lab in Oakland, Microgenesis emphasizes a drug-free, all-natural three-month treatment that addresses subclinical inflammation adversely affecting ovarian function and implantation.

EMBER Medical is a telehealth platform that facilitates immediate connections between patients and medical professionals, including physicians, nurses, and EMTs, within a five-minute walking distance. Founded in 2018 and based in San Francisco, California, EMBER Medical's mobile application provides users with the ability to engage in private audio and video consultations, ensuring timely medical assistance. The platform is designed to enhance healthcare accessibility, particularly in underserved regions, by enabling patients to receive quality remote care and allowing medical professionals to utilize a comprehensive suite of virtual clinic tools. EMBER Medical aims to streamline the healthcare experience by connecting individuals to the right care quickly and efficiently, promoting a more personalized approach to health management.

Sequential Skin is a diagnostic platform company targeting skin longevity and aging. Our team specialises in genetics, epigenetics, and the skin microbiome.

Sequential Skin is a diagnostic platform company targeting skin longevity and aging. Our team specialises in genetics, epigenetics, and the skin microbiome.

Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.

Biomage focuses on single-cell analysis to advance life sciences by providing innovative computational methods to derive insights from biological data. The company has developed the Biomage Single Cell Platform, which allows researchers to efficiently analyze single-cell RNA sequencing data. This platform transforms complex datasets into actionable biological insights, facilitating research in both academia and industry. By streamlining the data analysis process, Biomage empowers scientists to enhance drug target discovery while making the application of advanced sequencing technologies more accessible and cost-effective.

BiomeSense is revolutionizing human microbiome research by developing novel technologies to enable investigators to collect, store, and analyze the daily microbiome profiles of clinical trial participants in a low-cost, scalable way. By enabling daily profiling, the platform allows investigators the unprecedented ability to tie microbiome changes directly to clinical outcomes in real time, dramatically increasing the research discovery potential.

We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity Ranking, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access to precision oncology to improve patients' lives.

Mendel.ai develops artificial intelligence-based solutions aimed at enhancing clinical oncology research and improving patient care. Founded in 2005 and headquartered in San Jose, California, the company offers a range of software solutions that address various challenges in the clinical trial process. Its products include Read, which provides instant data abstraction; Retina, designed to minimize data loss during optical character recognition; Redact, which addresses privacy concerns in patient record sharing; Research, a clinical search engine; Recruit, facilitating patient prescreening and enrollment; and Enrich, which offers real-time access to real-world data from leading oncology clinics. By transforming unstructured electronic medical records and clinical literature into analytics-ready data, Mendel.ai aims to streamline global oncology research and automate clinical trials.

BioFeyn specializes in the development of nanocapsules designed for human medicine and aquaculture. These tiny molecular transporters effectively deliver nutrients, drugs, and natural products, enhancing fish health while minimizing environmental pollution. The company employs a targeted, modular delivery mechanism to ensure that essential nutrients and natural disease preventatives reach fish, thereby promoting the production of sustainable and nutritious farmed fish. BioFeyn's solutions are adaptable across various species and can be seamlessly integrated into existing supply chains, benefiting both human consumers and the planet. The team comprises experts in materials engineering, molecular biology, and medicine, reflecting a multidisciplinary approach to addressing challenges in health and sustainability.

Aluna is a healthcare company based in San Francisco, California, that specializes in respiratory management solutions for individuals with chronic lung conditions, including asthma, cystic fibrosis, and COPD. The company has developed a portable spirometry test device that is integrated with an interactive iPhone game, creating an engaging way for users to monitor their respiratory health. Aluna's health platform enables users, particularly children and their parents, to track asthma symptoms, manage medication, and monitor treatment progress. Additionally, the platform offers real-time data that can be shared with healthcare providers, facilitating better insights into asthma triggers and events. Founded in 2013, Aluna aims to improve the quality of life for those living with chronic respiratory conditions.

Moirai Biodesign develops RNA-based therapies and diagnostics for cancer. The company develops non-invasive tests for in-vitro and in-situ diagnosis of AML using the patients blood; in-vivo diagnosis systems for surgical assistance and patient monitoring; and therapeutical drugs for treating cancer. Its pipeline includes RNA biomarker discovery, plug and play bio device design, and platform delivery system. The company was founded in 2016 and is based in Ireland.

BioAesthetics Corporation, founded in 2015 as a spin-out from Tulane University, specializes in developing innovative reconstruction solutions for breast cancer patients who have undergone mastectomies. The company's primary product is a tissue-engineered nipple-areolar complex (NAC), designed to facilitate the regeneration of the nipple and areola during the breast reconstruction phase. This biologically derived graft serves as an acellular, off-the-shelf option for plastic and reconstructive surgeons, allowing the patient's own cells to integrate and restore the NAC. Currently in the pre-clinical phase, this patent-pending technology aims to improve surgical outcomes and enhance the quality of life for patients with incomplete or removed NACs due to disease, surgery, or birth defects. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

BioFeyn specializes in the development of nanocapsules designed for human medicine and aquaculture. These tiny molecular transporters effectively deliver nutrients, drugs, and natural products, enhancing fish health while minimizing environmental pollution. The company employs a targeted, modular delivery mechanism to ensure that essential nutrients and natural disease preventatives reach fish, thereby promoting the production of sustainable and nutritious farmed fish. BioFeyn's solutions are adaptable across various species and can be seamlessly integrated into existing supply chains, benefiting both human consumers and the planet. The team comprises experts in materials engineering, molecular biology, and medicine, reflecting a multidisciplinary approach to addressing challenges in health and sustainability.

BioFeyn specializes in the development of nanocapsules designed for human medicine and aquaculture. These tiny molecular transporters effectively deliver nutrients, drugs, and natural products, enhancing fish health while minimizing environmental pollution. The company employs a targeted, modular delivery mechanism to ensure that essential nutrients and natural disease preventatives reach fish, thereby promoting the production of sustainable and nutritious farmed fish. BioFeyn's solutions are adaptable across various species and can be seamlessly integrated into existing supply chains, benefiting both human consumers and the planet. The team comprises experts in materials engineering, molecular biology, and medicine, reflecting a multidisciplinary approach to addressing challenges in health and sustainability.

Optimize Health is a Seattle-based company that offers a digital healthcare platform focused on Remote Patient Monitoring (RPM) for outpatient medical practices. Founded in 2015, it provides software, equipment, and services designed to enhance patient engagement and compliance with new Medicare billing codes. Its platform simplifies the management of RPM programs by automatically tracking medication doses and sending reminders to patients through Bluetooth-enabled devices. This user-friendly approach aims to improve the experience for both patients and healthcare providers while enabling physicians to achieve profitability from the first month of implementation. The company’s offerings include a clinical call center and various support services to ensure effective patient monitoring.

renegade.bio is a biotechnology startup dedicated to developing and deploying high throughput diagnostics for the detection of novel infectious diseases.

Mobio Interactive Inc. is a Toronto-based company that specializes in developing digital tools aimed at enhancing mental health and performance for both consumers and clinical populations. Founded in 2014, Mobio has created applications such as Am Mindfulness, Wildflowers Mindfulness, and Actify Mindfulness, which provide medical-grade mindfulness training. These applications uniquely offer remote and objective assessments of mindfulness meditation efficacy by measuring various physiological indicators, including heart rate and blood oxygen saturation, before and after usage. Am Mindfulness, a key product, is a clinically validated digital therapeutic that allows users to engage with the platform securely and privately through mobile devices, independent of wearables. It has demonstrated effectiveness in clinical trials, outperforming placebo in multiple studies. Additionally, Mobio is involved in extensive clinical research in psycho-oncology, targeting one of the most stress-affected patient groups. The company also has offices in Zurich, Switzerland, and Shanghai, China.

Microgenesis SA is a biotechnology company focused on developing medical technologies and treatments for reproductive health. Established in 1992 and based in San José de la Rinconada, Spain, the company specializes in non-invasive tests that identify imbalances in vaginal and intestinal microbiota linked to infertility. Additionally, Microgenesis offers dual tests to assess microbiota imbalances related to endometrial immunological issues and provides tools and guidance for managing complex reproductive health cases. Their innovative fertility test and treatment aim to restore fertility potential, particularly for women who have previously experienced multiple IVF failures. Operating from a CLIA-certified lab in Oakland, Microgenesis emphasizes a drug-free, all-natural three-month treatment that addresses subclinical inflammation adversely affecting ovarian function and implantation.

Microgenesis SA is a biotechnology company focused on developing medical technologies and treatments for reproductive health. Established in 1992 and based in San José de la Rinconada, Spain, the company specializes in non-invasive tests that identify imbalances in vaginal and intestinal microbiota linked to infertility. Additionally, Microgenesis offers dual tests to assess microbiota imbalances related to endometrial immunological issues and provides tools and guidance for managing complex reproductive health cases. Their innovative fertility test and treatment aim to restore fertility potential, particularly for women who have previously experienced multiple IVF failures. Operating from a CLIA-certified lab in Oakland, Microgenesis emphasizes a drug-free, all-natural three-month treatment that addresses subclinical inflammation adversely affecting ovarian function and implantation.

Babybe GmbH is a medical device company based in Stuttgart, Germany, specializing in products designed for premature babies and their mothers. Founded in 2013, the company has developed the Babybe System, a unique bionic mattress that simulates the mother's heartbeat, breathing, and voice to establish a real-time connection with the infant during incubation. This innovative product not only facilitates skin-to-skin care when mothers are unable to hold their babies but also aims to enhance neurodevelopmental outcomes for preterm infants. By keeping mothers and their babies connected, the Babybe System helps improve recovery times, reduces costs for families, and increases efficiency in neonatal intensive care units. As of November 2020, Babybe operates as a subsidiary of Natus Medical Incorporated.

Strados Labs, LLC is a medical technology company based in Philadelphia, Pennsylvania, that focuses on innovating respiratory health management through advanced biosensors and artificial intelligence. Founded in 2016, Strados Labs develops a wearable device that provides real-time insights into respiratory metrics such as breathing speed, sounds, and patterns. This device is equipped with a continuous breathing sensor that enables remote monitoring of patients with respiratory conditions like asthma and chronic obstructive pulmonary disease. By connecting the device to a mobile application, patients and healthcare providers can access critical respiratory data, facilitating informed decision-making and improved management of respiratory health.

GlowDx is a company based in Midleton, Ireland, that specializes in the design and development of innovative diagnostics for tropical diseases. Incorporated in 2015, GlowDx focuses on decentralizing molecular testing through point-of-care technologies, allowing for local access to vital diagnostic services. By combining novel molecular technology with unique delivery models, the company aims to improve clinical outcomes and reduce both the economic and health burdens faced by patients. Through its efforts, GlowDx seeks to enhance the quality of life for individuals, enabling healthcare institutions to provide accurate diagnostics and ensuring patients receive essential information in a timely manner.

AnimalBiome focuses on improving the gut health of dogs and cats in the United States that suffer from chronic digestive disorders. The company offers microbiome-based supplements and non-invasive diagnostic tools designed to identify imbalances in the gut microbiome. Utilizing deoxyribonucleic acid sequencing, AnimalBiome's diagnostic services assess the balance of gut bacteria, allowing pet owners to gain insights into their pets' gut health. This information enables tailored supplementation aimed at restoring gut balance, ultimately promoting a healthier and happier life for pets.

FluidAI Medical is focused on developing an innovative implantable biochip equipped with biosensors designed to detect post-operative complications, including internal bleeding, fluid leakage, and infections within the abdominal cavity. This advanced biosensor continuously collects data, identifying complications as they arise, and provides real-time notifications to both patients and healthcare providers. Specifically, the device aims to manage risks associated with surgeries by monitoring for anastomotic leakage, which involves gastrointestinal fluid leaking into the abdominal cavity. The biosensor is integrated into a catheter, where it resides within the abdominal cavity, while a monitoring unit remains external. When the biosensor detects changes indicative of a leak, it transmits alerts through the catheter to the external monitor. Data is continuously uploaded to the cloud for further analysis, ensuring timely alerts are sent to patients' smartphones, prompting them to seek medical attention, while offering detailed information to their doctors. Founded in 2014 and based in Kitchener, Canada, FluidAI Medical serves physicians, surgeons, hospitals, and patients with its groundbreaking technology.

Every day we flush precious information on our bodies down the toilet. Bisu helps people capture these data and lead healthier, happier lives. Our product is a home health lab that provides personalized advice to help you look, feel and perform at your best, through easy, accurate urine and saliva tests. We are graduates of HAX, the world's leading hardware accelerator, and have won numerous awards including Johnson & Johnson Innovation, MedTech Innovator, the Edison Awards, UK Tech Rocketship Awards and the British Business Awards. At CES 2020 we won the IHS Markit Innovation Award and were named by CNET as one of the top health-tracking devices.

Ocular Technologies develops an integrated ocular telemedicine solution to improve access to eye doctors. The company brings eye specialists closer to patients by allowing an automated, remote eye exam.The company's product, Ocular-1, automates a traditional eye exam and sends a video of the exam to an eye specialist for review. Better diagnostics at the point of care improves results and reduces cost to the patient and the healthcare system.

DeepSpin GmbH, founded in 2019 and headquartered in Berlin, Germany, specializes in the development of an innovative artificial intelligence (AI)-based magnetic resonance imaging (MRI) system. This next-generation imaging machine is designed to be significantly smaller, lighter, and more affordable than conventional MRI systems. By utilizing generative topological design for its hardware and deep learning algorithms for image processing, DeepSpin aims to enhance the accessibility of medical imaging, making it available to patients worldwide. The company's technology seeks to modernize medical imaging, providing a standard of care that can reach previously underserved medical domains.

BrightCure Ltd. is a company based in London, United Kingdom, that specializes in developing probiotic-based therapies aimed at treating urinary tract infections (UTIs). Founded in 2019, BrightCure addresses the significant challenge of recurrent and difficult-to-treat UTIs, which affect a large portion of the global population, particularly women. Conventional UTI treatments often fall short in effectiveness and can lead to serious side effects, contributing to the rise of antibiotic-resistant infections. The company focuses on leveraging the natural microbiome to eliminate harmful bacteria while restoring beneficial flora. BrightCure's flagship product, a bioactive intimate cream, is designed to enhance the natural immune response and support urinary tract health. The UTI treatment market is projected to grow significantly, reflecting the urgent need for effective solutions. BrightCure has received recognition for its innovative approach, including seed investment from SOSV and accolades in various competitions, underscoring its potential impact in the healthcare sector.

BrightCure Ltd. is a company based in London, United Kingdom, that specializes in developing probiotic-based therapies aimed at treating urinary tract infections (UTIs). Founded in 2019, BrightCure addresses the significant challenge of recurrent and difficult-to-treat UTIs, which affect a large portion of the global population, particularly women. Conventional UTI treatments often fall short in effectiveness and can lead to serious side effects, contributing to the rise of antibiotic-resistant infections. The company focuses on leveraging the natural microbiome to eliminate harmful bacteria while restoring beneficial flora. BrightCure's flagship product, a bioactive intimate cream, is designed to enhance the natural immune response and support urinary tract health. The UTI treatment market is projected to grow significantly, reflecting the urgent need for effective solutions. BrightCure has received recognition for its innovative approach, including seed investment from SOSV and accolades in various competitions, underscoring its potential impact in the healthcare sector.

BrightCure Ltd. is a company based in London, United Kingdom, that specializes in developing probiotic-based therapies aimed at treating urinary tract infections (UTIs). Founded in 2019, BrightCure addresses the significant challenge of recurrent and difficult-to-treat UTIs, which affect a large portion of the global population, particularly women. Conventional UTI treatments often fall short in effectiveness and can lead to serious side effects, contributing to the rise of antibiotic-resistant infections. The company focuses on leveraging the natural microbiome to eliminate harmful bacteria while restoring beneficial flora. BrightCure's flagship product, a bioactive intimate cream, is designed to enhance the natural immune response and support urinary tract health. The UTI treatment market is projected to grow significantly, reflecting the urgent need for effective solutions. BrightCure has received recognition for its innovative approach, including seed investment from SOSV and accolades in various competitions, underscoring its potential impact in the healthcare sector.

Machine Medicine Limited develops a health monitoring system that uses computer vision and artificial intelligence in order to extract health metrics. The system tracks activities, walking patterns, detects falls and disease signs, and alert families when an intervention is needed. The company was founded in 2014 and is headquartered in London, United Kingdom.

renegade.bio is a biotechnology startup dedicated to developing and deploying high throughput diagnostics for the detection of novel infectious diseases.

Advanced Microbubbles Inc specializes in the development of microbubbles, which serve as ultrasound contrast agents for targeted drug delivery. Founded in 2020 and based in Newark, California, the company offers a range of products, including size-isolated microbubbles and biotin- or streptavidin-tagged variants. These microbubbles are designed for applications in ultrasound imaging, noninvasive cancer surgery, and enhancing drug delivery across challenging biological barriers, such as the blood-brain barrier. By focusing on precision drug and gene delivery, Advanced Microbubbles aims to improve treatment outcomes and reduce side effects for patients with neurological conditions and cancer.

Advanced Microbubbles Inc specializes in the development of microbubbles, which serve as ultrasound contrast agents for targeted drug delivery. Founded in 2020 and based in Newark, California, the company offers a range of products, including size-isolated microbubbles and biotin- or streptavidin-tagged variants. These microbubbles are designed for applications in ultrasound imaging, noninvasive cancer surgery, and enhancing drug delivery across challenging biological barriers, such as the blood-brain barrier. By focusing on precision drug and gene delivery, Advanced Microbubbles aims to improve treatment outcomes and reduce side effects for patients with neurological conditions and cancer.

Strados Labs, LLC is a medical technology company based in Philadelphia, Pennsylvania, that focuses on innovating respiratory health management through advanced biosensors and artificial intelligence. Founded in 2016, Strados Labs develops a wearable device that provides real-time insights into respiratory metrics such as breathing speed, sounds, and patterns. This device is equipped with a continuous breathing sensor that enables remote monitoring of patients with respiratory conditions like asthma and chronic obstructive pulmonary disease. By connecting the device to a mobile application, patients and healthcare providers can access critical respiratory data, facilitating informed decision-making and improved management of respiratory health.

Biomage focuses on single-cell analysis to advance life sciences by providing innovative computational methods to derive insights from biological data. The company has developed the Biomage Single Cell Platform, which allows researchers to efficiently analyze single-cell RNA sequencing data. This platform transforms complex datasets into actionable biological insights, facilitating research in both academia and industry. By streamlining the data analysis process, Biomage empowers scientists to enhance drug target discovery while making the application of advanced sequencing technologies more accessible and cost-effective.

Biomage focuses on single-cell analysis to advance life sciences by providing innovative computational methods to derive insights from biological data. The company has developed the Biomage Single Cell Platform, which allows researchers to efficiently analyze single-cell RNA sequencing data. This platform transforms complex datasets into actionable biological insights, facilitating research in both academia and industry. By streamlining the data analysis process, Biomage empowers scientists to enhance drug target discovery while making the application of advanced sequencing technologies more accessible and cost-effective.

Metabolomic Diagnostics Ltd. is a medical diagnostics company based in Little Island, Ireland, specializing in the early detection of pregnancy-related complications through innovative biomarker-based diagnostic solutions. Founded in 2011, the company has developed a mass spectrometry-based platform capable of analyzing multiple biomarkers simultaneously. This technology facilitates the predictive diagnosis of pre-eclampsia, a serious condition characterized by high blood pressure and proteinuria during pregnancy. By identifying diagnostic biomarker panels and translating them into clinical assays, Metabolomic Diagnostics aims to improve personalized care for pregnant women. The company's vision includes enhancing clinical decision-making and prenatal care by providing accurate risk assessments for complications such as gestational diabetes and preterm birth. Through collaboration with prenatal care providers, Metabolomic Diagnostics seeks to empower clinicians and pregnant women alike, ultimately aiming to improve pregnancy outcomes on a global scale.

renegade.bio is a biotechnology startup dedicated to developing and deploying high throughput diagnostics for the detection of novel infectious diseases.

renegade.bio is a biotechnology startup dedicated to developing and deploying high throughput diagnostics for the detection of novel infectious diseases.

DeepSpin GmbH, founded in 2019 and headquartered in Berlin, Germany, specializes in the development of an innovative artificial intelligence (AI)-based magnetic resonance imaging (MRI) system. This next-generation imaging machine is designed to be significantly smaller, lighter, and more affordable than conventional MRI systems. By utilizing generative topological design for its hardware and deep learning algorithms for image processing, DeepSpin aims to enhance the accessibility of medical imaging, making it available to patients worldwide. The company's technology seeks to modernize medical imaging, providing a standard of care that can reach previously underserved medical domains.

CASPR Biotech is a San Francisco-based company established in 2018 that specializes in developing a CRISPR-based platform for diagnosing antimicrobial resistances (AMR) and infectious diseases. The company focuses on creating portable diagnostic kits that enable the detection of specific DNA and RNA sequences, as well as signature amino acid sequences associated with infectious diseases and genetic mutations. By offering a simple, fast, and affordable solution, CASPR Biotech aims to assist healthcare providers in delivering efficient diagnostics within clinical and hospital settings.

sRNAlytics developed a computational platform to diagnose and subtype disease using small RNAs. We offer our technology and services to drug developers to identify companion diagnostics and uncover new therapeutic targets.

Lura Health is a company that specializes in developing tooth-mounted sensors designed to monitor oral health through saliva analysis. Founded in 2016 and based in Cambridge, Massachusetts, Lura Health's wireless intra-oral sensors allow users to continuously track key diagnostic metrics related to their oral environment. The sensors are designed to sit comfortably on a single tooth and monitor oral acidity, transmitting data to a mobile application. This technology provides users with meaningful insights and instant feedback, empowering them to take control of their health and improve personal health management by setting and achieving health goals.

BioSapien is a biotech startup that focuses on developing a 3D printed drug delivery platform to provide FDA approved drugs. The startup's device allows chemotherapy to be delivered intravenously through a controlled drug release and enables physicians to reduce harmful side-effects and dramatically reduce costs. BioSapien was established in 2018 and is based in New York.

Aksense is an innovative company focused on developing affordable and portable nucleic acid-based diagnostic panels for the rapid and accurate detection of pathogens. Its flagship product is the first portable rapid infection diagnostic biosensor designed to improve healthcare quality and safety. By facilitating early detection and treatment of infections, Aksense's technology aims to enhance antibiotic prescribing practices and reduce the spread of infections. This approach not only improves patient outcomes but also supports public health initiatives by allowing users to recover faster through cost-effective molecular testing solutions.